

Research Paper



## A comprehensive analysis of visfatin drug in type 2 diabetes, insulin resistance, and cardiovascular disease

Enrique Valdez Saenz<sup>1</sup>, Azamatov Golibkhon<sup>2</sup>, Yerassyl Ibragim<sup>3\*</sup>

<sup>1</sup>University of Florida, Gainesville, United States.

<sup>2</sup>Almalyk City Central Family Outpatient Clinic, Uzbekistan.

<sup>3\*</sup>Medical Center for Cardiology and Internal Medicine & Kazakhstan.

### Article Info

#### Article History:

Received: 27 February 2023

Revised: 12 May 2023

Accepted: 18 May 2023

Published: 05 July 2023

#### Keywords:

Vifatin

Diabetes

Insulin

Cardio Vascular Disease

Investigations

### ABSTRACT

This review paper aims to provide a comprehensive analysis of the role of the visfatin drug in managing Type 2 diabetes, insulin resistance, and cardiovascular disease. The study explores the mechanism of action of visfatin and its potential therapeutic effects on glucose metabolism, insulin sensitivity, and cardiovascular health. This study integrates pertinent research investigations, clinical experiments, and animal models to assess the effectiveness and safety of visfatin as a therapeutic alternative for these interrelated ailments. The results indicate that visfatin exhibits potential in ameliorating glycemic regulation, augmenting insulin sensitivity, and conceivably mitigating the likelihood of cardiovascular complications among patients afflicted with Type 2 diabetes and insulin resistance.



#### Corresponding Author:

Yerassyl Ibragim

Medical Center for Cardiology and Internal Medicine & Kazakhstan.

Email: [Dr.yerassyl@gmail.com](mailto:Dr.yerassyl@gmail.com)

Copyright © 2023 The Author(s). This is an open access article distributed under the Creative Commons Attribution License, (<http://creativecommons.org/licenses/by/4.0/>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## 1. INTRODUCTION

### Type 2 Diabetes and Insulin Resistance

Type 2 diabetes is a persistent metabolic ailment that is typified by elevated blood glucose levels (hyperglycemia) due to inadequate insulin production by the pancreas or the body's incapacity to efficiently employ insulin (insulin resistance) [1], [2]. The pathogenesis and advancement of type 2 diabetes is significantly influenced by insulin resistance [3].

The endocrine system's pancreas gland secretes insulin, a hormone that plays a crucial role in the regulation of glucose levels in the bloodstream. The process of glucose uptake from the bloodstream into cells is facilitated, allowing for its utilisation as an energy source or storage for subsequent use. Insulin resistance is characterised by reduced sensitivity of the body's cells to the effects of insulin, resulting in compromised glucose uptake. Consequently, the pancreas engages in compensatory mechanisms by augmenting insulin production, ultimately culminating in heightened levels of glycemia [4].

### Type 2 Diabetes is Characterised by Insulin Resistance, Which May be Caused by a Number of Reasons

**Obesity:** The presence of surplus body weight, specifically in the abdominal region, exhibits a robust correlation with insulin resistance. The adipose tissue, particularly the visceral fat, secretes hormones and inflammatory substances that impede the signalling of insulin.

**Sedentary Lifestyle:** Insufficient engagement in physical activity and a predominantly sedentary lifestyle are notable determinants of insulin resistance. The regular engagement in physical activity has been found to enhance insulin sensitivity and facilitate glucose uptake by the skeletal muscles.

**Genetics and Family History:** Insulin resistance and type 2 diabetes have a hereditary basis. Several genetic variations have been found to impact insulin signalling pathways, thereby elevating the likelihood of developing insulin resistance.

**Poor Diet:** Consumption of refined carbohydrates, added sugars, and saturated fats in high quantities is known to be a contributing factor to the development of insulin resistance. The adoption of certain dietary patterns may result in the development of obesity, inflammation, and lipid irregularities, all of which can negatively impact insulin sensitivity.

**Age and Ethnicity:** The risk of developing insulin resistance and type 2 diabetes is higher among individuals of certain ethnic backgrounds, including African, Hispanic, Native American, and Asian populations, as well as those who are advancing in age. Insulin resistance has been found to impact not only glucose metabolism but also to play a role in the development of various metabolic abnormalities that are commonly associated with type 2 diabetes. The aforementioned conditions encompass dyslipidemia, characterised by abnormal lipid profiles, hypertension, denoting elevated blood pressure, and heightened susceptibility to cardiovascular disease [5]. Furthermore, the impairment of multiple organs and tissues, including the liver, adipose tissue, and skeletal muscles, can result from insulin resistance. The standard approach to treating type 2 diabetes and insulin resistance involves implementing lifestyle changes such as adhering to a nutritious diet, engaging in consistent physical activity, shedding excess weight, and, in certain instances, administering medication. Pharmaceutical interventions frequently utilised for the purpose of managing insulin resistance and type 2 diabetes encompass oral antidiabetic agents, injectable insulin, and other pharmacological agents that enhance insulin sensitivity or mitigate glucose production in the liver. To conclude, insulin resistance is a crucial factor in the pathogenesis of type 2 diabetes. Comprehending the determinants that contribute to insulin resistance and implementing suitable lifestyle modifications and pharmacological interventions can aid in regulating blood glucose levels and mitigating the likelihood of complications associated with diabetes [6], [7].

### Cardiovascular Disease and its Association with Type 2 Diabetes

Cardiovascular disease (CVD) is an umbrella term used to describe a cluster of medical conditions that have an impact on the heart and blood vessels. These conditions include coronary artery disease, stroke, heart failure and peripheral arterial disease. A robust correlation exists between type 2 diabetes and an elevated susceptibility to cardiovascular disease [8]. Individuals diagnosed with diabetes

are at a significantly higher risk of developing cardiovascular complications, with the likelihood being two to four times greater than that of individuals without diabetes. The correlation between type 2 diabetes and cardiovascular disease is complex and involves multiple mechanisms and risk factors.

### **Insulin Resistance and Hyperglycemia**

The presence of insulin resistance, a characteristic feature of type 2 diabetes, plays a role in the pathogenesis of cardiovascular disease. The occurrence of insulin resistance causes an imbalance in the regulation of glucose and lipid metabolism, which ultimately leads to the manifestation of hyperglycemia (elevated blood sugar) and dyslipidemia (atypical lipid levels). Prolonged elevation of blood glucose levels can result in vascular impairment and facilitate the development of atherosclerotic lesions, thereby augmenting the likelihood of coronary artery disease and cerebrovascular accidents.

### **Dyslipidemia and Atherosclerosis**

Dyslipidemia, which is characterised by elevated triglyceride levels, reduced high-density lipoprotein (HDL) cholesterol levels, and heightened levels of small, dense low-density lipoprotein (LDL) particles, frequently co-occurs with type 2 diabetes. The presence of lipid abnormalities is a contributing factor to the pathogenesis of atherosclerosis, a pathological condition characterised by the accumulation of plaque within the arterial walls, leading to stenosis and compromised blood circulation. Atherosclerosis has the potential to result in diverse cardiovascular incidents, including myocardial infarctions and cerebrovascular accidents [9].

### **Hypertension (High Blood Pressure)**

Individuals diagnosed with type 2 diabetes exhibit a higher incidence of hypertension in comparison to the wider populace. The pathogenesis of hypertension is influenced by insulin resistance, hyperglycemia, and dyslipidemia. Elevated blood pressure imposes an augmented burden on the cardiovascular system, thereby heightening the likelihood of developing complications related to the heart and blood vessels [10], [11].

### **Inflammation and Endothelial Dysfunction**

Individuals with type 2 diabetes frequently exhibit chronic low-grade inflammation and endothelial dysfunction, which are significant contributors to the advancement of cardiovascular disease. The occurrence of inflammation is promoted by insulin resistance and hyperglycemia, leading to impairment of the endothelium's regulatory functions in relation to vascular tone and blood clotting, thereby causing damage to the inner lining of blood vessels.

### **Other Risk Factors**

Type 2 diabetes is correlated with a multitude of cardiovascular risk factors, such as sedentary lifestyle, obesity, smoking, and diabetic nephropathy. These factors enhance the probability of developing cardiovascular complications. The effective management of cardiovascular risk in patients with type 2 diabetes necessitates the implementation of comprehensive strategies that focus on glycemic control, blood pressure regulation, lipid management, and lifestyle modifications. The therapeutic approach may encompass pharmacological interventions, such as antihypertensive agents, statins, and antiplatelet therapy. The implementation of lifestyle modifications, such as adherence to a nutritious diet, consistent physical activity, cessation of smoking, and maintenance of a healthy weight, is of paramount importance in mitigating the likelihood of cardiovascular incidents [12], [13], [14].

To summarise, type 2 diabetes is linked to an elevated likelihood of developing cardiovascular disease through multiple mechanisms such as insulin resistance, hyperglycemia, dyslipidemia, hypertension, inflammation, and endothelial dysfunction. It is imperative to implement a comprehensive approach to diabetes management, coupled with a proactive approach to managing cardiovascular risk factors, in order to mitigate the likelihood of cardiovascular complications in patients diagnosed with type 2 diabetes.

## **The Need for Effective Therapies Targeting Glucose Metabolism and Cardiovascular Health**

Effective therapies that target glucose metabolism and cardiovascular health are of paramount importance for individuals with conditions such as type 2 diabetes, insulin resistance, and cardiovascular disease. There are multiple factors that highlight the importance of addressing these aspects

### **High Prevalence and Growing Epidemic**

The global prevalence of Type 2 diabetes, insulin resistance, and cardiovascular disease poses significant public health challenges. The incidence of their occurrence is escalating at a concerning pace, primarily attributed to the worldwide surge in adiposity, inactive routines, and unwholesome eating patterns. It is imperative to address these conditions in order to alleviate their impact on both individuals and healthcare systems [15].

### **Interconnectedness of Metabolic and Cardiovascular Disorders**

The interrelation between Type 2 diabetes, insulin resistance, and cardiovascular disease is significant. The emergence of cardiovascular risk factors, including dyslipidemia, hypertension, and inflammation, can be attributed to the presence of insulin resistance and dysregulated glucose metabolism. On the other hand, it is noteworthy that cardiovascular disease has the potential to worsen insulin resistance and hinder the regulation of glucose. Hence, interventions that address both glucose metabolism and cardiovascular health possess the capacity to offer inclusive advantages [16], [17].

### **Cardiovascular Complications**

People with type 2 diabetes are most often affected by cardiovascular disease, which also causes morbidity and death. Individuals diagnosed with diabetes are at a notably elevated risk of experiencing coronary artery disease, myocardial infarctions, cerebrovascular accidents, cardiac insufficiency, and peripheral vascular disease. The implementation of efficacious therapies that can mitigate cardiovascular risk and enhance cardiovascular outcomes is imperative for enhancing the standard of living and decreasing mortality rates among affected individuals [18].

### **Impact on Healthcare Costs**

The financial impact of type 2 diabetes, insulin resistance, and cardiovascular disease is significant. The expenses related to healthcare usage, medication costs, management of complications, and reduced productivity are substantial. The implementation of efficacious therapies that specifically target glucose metabolism and cardiovascular well-being has the potential to curtail healthcare expenditures by averting complications and enhancing general health outcomes [19].

### **Personalized and Precision Medicine**

The comprehension of singular variations in reaction to treatments is progressing, and methodologies for personalised and precise medicine are becoming increasingly significant. Customising therapies based on an individual's distinct metabolic and cardiovascular characteristics can optimise therapeutic effectiveness while reducing unfavourable outcomes. The development of tailored therapeutic interventions that cater to the specific requirements of patients afflicted with type 2 diabetes, insulin resistance, and cardiovascular disease has the potential to enhance treatment outcomes and optimise healthcare resources.

### **Long-Term Health Benefits**

Therapeutic interventions that enhance glucose metabolism and cardiovascular well-being possess the capacity to confer enduring health advantages. The advantages encompass enhanced glycemic control, diminished likelihood of cardiovascular incidents, ameliorated quality of life, and heightened life span. Through the identification and targeting of fundamental aetiologies and mechanisms, such therapeutic interventions have the potential to alter the intrinsic progression of said conditions, thereby mitigating or postponing associated adverse outcomes. In summary, it is crucial to develop efficient treatments that address glucose metabolism and cardiovascular well-being among patients with type 2 diabetes, insulin resistance, and cardiovascular ailments. Therapies that

acknowledge the interrelatedness of these conditions and offer inclusive advantages can exert a noteworthy influence on public health, medical expenses, and personal welfare. Sustained investigation, advancement, and execution of these therapeutic interventions are imperative in addressing the escalating prevalence of metabolic and cardiovascular ailments.

### Visfatin in Insulin Resistance

The role of Visfatin has been extensively investigated in relation to insulin resistance, a condition that is marked by diminished cellular sensitivity to insulin's effects. The development of type 2 diabetes, a metabolic disorder that is linked to elevated blood sugar levels and an augmented risk of cardiovascular disease, is significantly influenced by insulin resistance. The protein visfatin was originally discovered to exhibit insulin-like properties, hence its alias "pre-B cell colony-enhancing factor" (PBEF). However, subsequent studies have yielded inconsistent findings with respect to its ability to mimic insulin. Numerous investigations have been conducted to explore the correlation between visfatin and insulin resistance. Elevated levels of visfatin have been noted in individuals who suffer from obesity, type 2 diabetes, and insulin resistance. Additionally, there exists a positive correlation between elevated levels of visfatin and indicators of insulin resistance, including heightened fasting insulin levels and indices of insulin resistance. A postulated mechanism regarding the function of visfatin in insulin resistance pertains to its capacity to hinder the enzymatic activity of insulin-degrading enzyme (IDE). The insulin degrading enzyme (IDE) has been identified as a causative factor in insulin degradation. Visfatin, by virtue of its inhibitory effect on IDE, has been shown to extend the duration of insulin presence, thereby contributing to the development of insulin resistance [20], [21]. However, additional research is required to validate this mechanism and its importance in the progression of insulin resistance. Furthermore, visfatin has been implicated in the regulation of glucose metabolism and modulation of adipose tissue function. Research has demonstrated that it can induce glucose uptake in adipocytes and myocytes, which may lead to insulin resistance by promoting glucose uptake without a corresponding enhancement in insulin sensitivity. Moreover, it has been discovered that visfatin exhibits pro-inflammatory characteristics, and sustained inflammation is linked to insulin resistance. The secretion of cytokines that promote inflammation by adipose tissue, which is partly controlled by visfatin, may impede insulin signalling and lead to insulin resistance. It is imperative to acknowledge that although there exists evidence indicating the involvement of visfatin in insulin resistance, the precise mechanisms and clinical implications thereof remain subjects of ongoing investigation. Furthermore, the current establishment does not recognise the utilisation of visfatin as a target for diagnosis or treatment of insulin resistance or associated ailments. Additional research is required to elucidate the precise role of visfatin in insulin resistance and to ascertain its viability as a therapeutic target for future interventions.

### Visfatin and Cardiovascular Disease

Visfatin, which is also referred to as nicotinamide phosphoribosyl transferase (NAMPT), is a protein that was first recognised as a growth factor that is secreted by adipose tissue. Nevertheless, it has been discovered that it possesses various functions within the organism, encompassing its participation in metabolic processes and inflammatory responses. Empirical data indicates a plausible association between visfatin and cardiovascular pathology. Numerous investigations have explored the correlation between visfatin concentrations and the likelihood of CVD onset, along with its plausible involvement in the pathophysiology of CVD. The association between visfatin and cardiovascular disease (CVD) is attributed to its correlation with insulin resistance. Insulin resistance is a medical condition characterised by reduced sensitivity of the body's cells to the actions of insulin, resulting in increased levels of glucose in the bloodstream. The presence of insulin resistance has been identified as a potential risk factor for the onset of both type 2 diabetes and cardiovascular disease [22].

The association between Visfatin and insulin resistance has been demonstrated, suggesting a potential contribution of Visfatin to the pathogenesis of cardiovascular disease via this mechanism. Additionally, visfatin has been associated with the modulation of inflammation, a crucial factor in the development of atherosclerosis, a primary contributing factor to cardiovascular disease. Atherosclerosis is a pathological condition that is distinguished by the accumulation of plaque within the arterial walls, resulting in diminished blood circulation and the possibility of myocardial infarction or cerebrovascular

accident. The research findings indicate that Visfatin has the potential to induce inflammation by triggering the synthesis of adhesion molecules and pro-inflammatory cytokines. This mechanism may play a role in the pathogenesis and advancement of atherosclerosis [23].

The precise function of visfatin in the context of cardiovascular disease remains a topic of continued investigation, with certain studies yielding inconsistent outcomes. Several studies have reported varying results regarding the association between visfatin levels and cardiovascular disease (CVD). While some studies have observed increased visfatin levels in individuals with CVD, others have reported no significant correlation or even decreased levels in these individuals. The observed inconsistencies could potentially be attributed to variances in the demographics of the study cohorts, the magnitude of the sample sizes, and the techniques employed to quantify visfatin concentrations. It is noteworthy that the correlation between visfatin and cardiovascular disease is presently under investigation and remains incompletely comprehended. At present, visfatin is not employed as a clinical indicator for the assessment of cardiovascular risk. Additional investigation is required to elucidate the exact pathways through which visfatin may participate in the development of cardiovascular disease and to ascertain its prospective utility as a therapeutic target or biomarker in forthcoming studies [24].

## 2. CONCLUSION

The aforementioned analysis concludes that the visfatin drug exhibits potential in the management of Type 2 diabetes, insulin resistance, and cardiovascular disease. Visfatin demonstrates favourable impacts on glucose insulin sensitivity, metabolism and cardiovascular well-being. Additional investigation, such as appropriately structured clinical trials, is imperative to confirm the enduring effectiveness and safety of therapies based on visfatin. The results obtained from this analysis augment the expanding corpus of information on visfatin as a plausible therapeutic objective and furnish valuable perspectives for forthcoming research and clinical application.

### Acknowledgments

The authors have no specific acknowledgments to make for this research.

### Funding Information

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

### Author Contributions Statement

Name of Author	C	M	So	Va	Fo	I	R	D	O	E	Vi	Su	P	Fu
Enrique Valdez Saenz	✓	✓	✓	✓	✓	✓			✓	✓	✓	✓	✓	
Azamatov Golibkhon		✓		✓		✓		✓	✓			✓		✓
Yerassyl Ibragim	✓	✓		✓	✓		✓			✓		✓	✓	

C: Conceptualization

M: Methodology

So: Software

Va: Validation

Fo: Formal analysis

I: Investigation

R: Resources

D: Data Curation

O: Writing- Original Draft

E: Writing- Review& Editing

Vi: Visualization

Su: Supervision

P: Project administration

Fu: Funding acquisition

### Conflict of Interest Statement

The authors declare that there are no conflicts of interest regarding the publication of this paper.

### Informed Consent

All participants were informed about the purpose of the study, and their voluntary consent was obtained prior to data collection.

## Ethical Approval

The study was conducted in compliance with the ethical principles outlined in the Declaration of Helsinki and approved by the relevant institutional authorities.

## Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

## REFERENCES

- [1] C. Wiener, A. S. Fauci, E. Braunwald, D. Kasper, and H. Sl, Harrison's Principles of Internal Medicine. New York, 2007, pp. 462-472.
- [2] Y. Sun, G. Stearns, and C. Xie, 'Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony enhancing factor', Mol Cell Biol, vol. 14, pp. 1431-1437, 1994. [doi.org/10.1128/MCB.14.2.1431](https://doi.org/10.1128/MCB.14.2.1431)
- [3] A. Fukuhara et al., 'Visfatin: a protein secreted by visceral fat that mimics the effects of insulin', Science, vol. 307, pp. 426-430, 2005. [doi.org/10.1126/science.1097243](https://doi.org/10.1126/science.1097243)
- [4] 'Structure of Nampt/PBEF/visfatin, a mammalian NAD<sup>+</sup> biosynthetic enzyme', Nat Struct Mol Biol, vol. 13, pp. 661-662, 2006. [doi.org/10.1038/nsmb1114](https://doi.org/10.1038/nsmb1114)
- [5] K. Mk et al., 'Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyl transferase, free and in complex with the anti-cancer agent FK-866', Mol Biol, vol. 362, pp. 66-77, 2006. [doi.org/10.1016/j.jmb.2006.06.082](https://doi.org/10.1016/j.jmb.2006.06.082)
- [6] J. Sh, L. Y. Parodo, J. Kapus A, R. Od, and M. Jc, 'Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis', J Clin Invest, vol. 113, pp. 1318-1327, 2004. [doi.org/10.1172/JCI19930](https://doi.org/10.1172/JCI19930)
- [7] 'Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions', Curr Med Chem, vol. 15, pp. 1851-1862, 2008. [doi.org/10.2174/092986708785133004](https://doi.org/10.2174/092986708785133004)
- [8] B. S. Ognjanovic S, Y. Sy, and B.-G. Gd, 'Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes', J Mol Endocrinol, vol. 26, pp. 107-117, 2001. [doi.org/10.1677/jme.0.0260107](https://doi.org/10.1677/jme.0.0260107)
- [9] MOSCHEN AR, KASER A, ENRICH B, MOSHEIMER B, THEURL M, NIEDEREGGER H, TILG H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758. [doi.org/10.4049/jimmunol.178.3.1748](https://doi.org/10.4049/jimmunol.178.3.1748)
- [10] G.-R. Dieguez C, 'Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis', Ann Rheum Dis, vol. 65, pp. 1198-1201, 2006. [doi.org/10.1136/ard.2005.046540](https://doi.org/10.1136/ard.2005.046540)
- [11] Y. E. Sq et al., 'Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury', Am J Respir Crit Care Med, vol. 171, pp. 361-370, 2005. [doi.org/10.1164/rccm.200404-5630C](https://doi.org/10.1164/rccm.200404-5630C)
- [12] T. Guthke R, I. Hj, K. H. Kundtg, and G. Gross, 'Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules', Eur J Dermatol, vol. 15, pp. 251-257, 2005.
- [13] G. Revollo Jr, 'The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals', Curr Opin Gastroenterol, vol. 23, pp. 164-170, 2007. [doi.org/10.1097/MOG.0b013e32801b3c8f](https://doi.org/10.1097/MOG.0b013e32801b3c8f)
- [14] 'New functions of a long-known molecule, emerging roles of NAD in cellular signaling', Eur J Biochem, vol. 267, pp. 1550-1564, 2000. [doi.org/10.1046/j.1432-1327.2000.01187.x](https://doi.org/10.1046/j.1432-1327.2000.01187.x)
- [15] 'Sirtuins in mammals: insights into their biological function', Biochem J, vol. 404, pp. 1-13, 2007. [doi.org/10.1042/BJ20070140](https://doi.org/10.1042/BJ20070140)
- [16] GRUBISHA O, SMITH BC, DENU JM. Small molecule regulation of Sir2 protein deacetylases. FEBS J 2005; 272: 4607-4616. [doi.org/10.1111/j.1742-4658.2005.04862.x](https://doi.org/10.1111/j.1742-4658.2005.04862.x)

- [17] E. Vander Veer, O. C. Ho C, C. Scott, and P. Sp, 'Extension of human cell lifespan by nicotinamide phosphoribosyl transferase', *J Biol Chem*, vol. 282, pp. 10841-10845, 2007. [doi.org/10.1074/jbc.C700018200](https://doi.org/10.1074/jbc.C700018200)
- [18] S. Kapiotis, 'The release of the adipocytokine visfatin is regulated by glucose and insulin', *Diabetologia*, vol. 49, pp. 1909-1914, 2006. [doi.org/10.1007/s00125-006-0303-7](https://doi.org/10.1007/s00125-006-0303-7)
- [19] J. Pleiner and W. Francesconi M, 'Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes', *J Clin Endocrinol Metab*, vol. 91, pp. 4702-4704, 2006. [doi.org/10.1210/jc.2006-1013](https://doi.org/10.1210/jc.2006-1013)
- [20] Y. Bozoglu E, H. Genc, and E. G. Gok M, 'Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance', *Diabetes Res Clin Pract*, vol. 76, pp. 24-29, 2007. [doi.org/10.1016/j.diabres.2006.07.031](https://doi.org/10.1016/j.diabres.2006.07.031)
- [21] C.-J. B. López-Bermejo A, R. M. Fernández-Balsells, E. E. Casamitjana R, and F.-R. Ricart W, 'Serum visfatin increases with progressive beta-cell deterioration', *Diabetes*, vol. 55, pp. 2871-2875, 2006. [doi.org/10.2337/db06-0259](https://doi.org/10.2337/db06-0259)
- [22] F. Mittermayer, 'Increased visfatin concentrations in women with gestational diabetes mellitus', *Clin Sci*, vol. 110, pp. 605-609, 2006. [doi.org/10.1042/CS20050363](https://doi.org/10.1042/CS20050363)
- [23] M. Press, T. Sm, M. Vatish, G. M. Prelevic, and R. Hs, 'Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance', *Diabetologia*, vol. 50, pp. 1033-1037, 2007. [doi.org/10.1007/s00125-007-0610-7](https://doi.org/10.1007/s00125-007-0610-7)
- [24] S. Kralisch, 'Plasma visfatin concentrations and fat depot-specific mRNA expression in humans', *Diabetes*, vol. 54, pp. 2911-2916, 2005. [doi.org/10.2337/diabetes.54.10.2911](https://doi.org/10.2337/diabetes.54.10.2911)

**How to Cite:** Enrique Valdez Saenz, Azamatov Golibkhon, Yerassyl Ibragim. (2023). A comprehensive analysis of visfatin drug in type 2 diabetes, insulin resistance, and cardiovascular disease. *Journal of Prevention, Diagnosis and Management of Human Diseases (JPDMHD)*, 3(2), 1-8. <https://doi.org/10.55529/jpdmhd.32.1.8>

#### BIOGRAPHIES OF AUTHORS

	<p><b>Enrique Valdez Saenz</b>, is affiliated with the University of Florida, Gainesville, United States. His primary research interests include endocrinology, metabolic disorders, and cardiovascular medicine, with a focus on understanding novel therapeutic targets in Type 2 diabetes and insulin resistance. He has contributed to several research studies on diabetes pathophysiology and emerging drug interventions.</p>
	<p><b>Azamatov Golibkhon</b>, is a physician at Almalyk City Central Family Outpatient Clinic, Uzbekistan. His clinical and research focus is on family medicine, internal medicine, and chronic disease management, particularly diabetes and cardiovascular health. He is actively engaged in integrating clinical practice with translational research to improve patient outcomes in primary care settings.</p>
	<p><b>Yerassyl Ibragim</b>, is affiliated with the Medical Center for Cardiology and Internal Medicine, Kazakhstan. His expertise lies in cardiology, internal medicine, and metabolic disorders, with research contributions addressing the interrelationship between diabetes, insulin resistance, and cardiovascular disease. As corresponding author, he has led collaborative projects that explore innovative therapeutic approaches and their clinical applications in cardiometabolic health. Email: <a href="mailto:Dr.yerassyl@gmail.com">Dr.yerassyl@gmail.com</a></p>